News

A hope for reducing treatment burden for wet age-related macular degeneration with a sustained-release vorolanib intravitreal insert

Preliminary results of PST-611-CT1 are anticipated early 2026, subject to patient recruitment.

Phil Lai, MD, chief medical officer of Perfuse Therapeutics, said the company's goal is to pioneer disease-modifying treatment that targets an underlying pathology of ischemia

In honor of Ophthalmology Times’ 50th anniversary, anterior segment surgeons attending ASCRS 2025 weigh in on the innovations that defined modern ophthalmology.

MHRA issues precautionary recall for Zaditen eye drops due to potential microbial contamination risk

A precautionary recall of Zaditen eye drops is issued due to potential microbial contamination, affecting batch 4V64. No adverse events reported.

The VISTA trial is evaluating and comparing 2 dose levels of laru-zova with an untreated control group for the treatment of X-linked retinitis pigmentosa (XLRP).

EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in vision and safety.

Research from the iMIND lab at Duke University.

SpaMedica to offer free transport for all NHS cataract patients, supporting community care and reducing health inequalities.

Investigators reported the oral therapy was well-tolerated in trials for early treatment of non-proliferative diabetic retinopathy and associated oedema

Both 6-month trials were randomized, controlled studies that evaluated PER-001 delivered in a slow-release, dissolvable implant injected intravitreally every 6 months.

Boehringer Ingelheim initiates THULITE study, exploring an oral treatment for diabetic macular edema, aimed to improve patient care and convenience.

The company notes that the workforce reduction is expected to provide annual cash compensation cost savings of approximately $15 million and offsets additional expenses expected based on the accelerated timelines for the 4FRONT clinical trials.

LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD.

Retinal imaging and the future of early Alzheimer diagnosis.

At the 2025 International SPECTRALIS Symposium—And Beyond (ISS), Chauhan discussed how two-photon microscopy enables precise, non-invasive monitoring of retinal ganglion cell function in living subjects.

The imaging innovation project is named after the company's co-founder Gerhard Zinser, PhD

New clinical trials reveal PER-001 as a new treatment for glaucoma and diabetic retinopathy, showing significant vision improvements and safety.

Catch up on this week's highlights in retina.

A new study links urinary metabolites from organophosphorus pesticides to increased age-related macular degeneration risk.

Recapping a recent conversation led by Dilsher S. Dhoot, MD.

AAV204 is a novel adeno-associated virus (AAV) capsid from the AIM capsid library licensed by Abeona from the University of North Carolina at Chapel Hill.

New technologies and a proactive mindset are transforming how glaucoma is diagnosed and treated—and redefining what “controlled” really means.

Lupin Limited secures FDA approval for Loteprednol Etabonate Ophthalmic Gel, enhancing treatment options for postoperative ocular inflammation and pain.

In-orbit imaging drives innovation in terrestrial telemedicine, the NASA scientist explained

The program allows patients to undergo genetic testing and high-resolution retinal imaging anonymously and provide insights into both ocular and systemic diseases.